Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10th

A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis for positive claims. The lawsuit was triggered after Revolution Medicines alleged patent infringement and trade secret misappropriation on April 28, 2026, causing Erasca's stock to plunge 48% from $19.15 to $9.90 per share. Investors who purchased shares between January 14, 2025 and April 26, 2026 have until August 10, 2026 to apply as lead plaintiff.